Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Souvenaid

- PMLiVE

Horizon looks bright as FDA panel backs eye drug teprotumumab

First alternative to surgery for proptosis

- PMLiVE

Novel endpoints in the digital age

Redesigning the goalposts

- PMLiVE

Brexit nears as Conservatives sweep to victory in election

British pharma association 'looks forward to working with the new Government'

- PMLiVE

House Democrats finally pass landmark drug pricing bill

Proposed legislation met with harsh criticism from pharma industry

- PMLiVE

FDA grants surprise OK to Sarepta’s DMD therapy after earlier rejection

Initially had concerns about infection risks and kidney toxicity

- PMLiVE

AZ, Daiichi Sankyo strengthen case for HER2 candidate

Will rival Roche's HER2 franchise if approved

- PMLiVE

Biologic patent exclusivity scrapped in new US trade deal

Drugmakers dealt a blow in latest trade negotiations

- PMLiVE

UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe

First new drug for the disease in the EU since 2010

- PMLiVE

Intec battered as Novartis ducks out of Accordion collaboration

Shares fell by more than 12% after the annoucement

Bristol Myers Squibb logo

BMS’ oral maintenance therapy boosts survival in AML patients

Drug improved survival by almost ten months

- PMLiVE

J&J appeals Oklahoma opioid verdict, claiming ‘errors’ in trial

Cites misuse of public nuisance laws as grounds for appeal

Sanofi reception

Sanofi narrows focus, shedding diabetes and cardiovascular research

New CEO Paul Hudson reveals strategy update

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links